By Reuters | BENGALURU |
Topics Bharat Biotech | Coronavirus Vaccine | Coronavirus Tests
India's Bharat Biotech is aiming to have a production capacity of about 700 million doses of its COVID-19 vaccine this year, according to a top executive of the biotechnology company.
The vaccine candidate, COVAXIN, received emergency use approval from India's drugs regulator on Sunday, a move that faced questions from industry experts and opposition lawmakers due to lack of efficacy data. Efficacy data from the company's ongoing late-stage trial should be available by March, Krishna Ella, chairman and managing director.....
This article is no longer available in our repository.
There could be multiple reasons for this.
You could try searching for this headline on the source website (bloomberg.com).